The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.
Editor’s note: This report has been updated to clarify those behind the policy proposal. A coalition of former congressional staffers and federal health leaders is putting forward a health care policy ...
You need to brace for changing costs.
The Trump administration decided to put the pilot on hold until at least 2027.
Updated policies mean the CMS is projected to pay about 2.48 percent more to Medicare Advantage and Part D insurance plans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results